Clinical Trials
73 trialsNCT02101853 2026-06-03
Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT02112916 2026-06-03
Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT06317662 2026-06-03
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT02883049 2026-06-02
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
National Cancer Institute (NCI)
Phase 3 Completed
NCT07387926 2026-05-19
Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)
Novartis
Phase 1/2 Not yet recruiting
NCT03286634 2026-05-11
ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016
National Hospital Organization Nagoya Medical Center
Phase 2 Active not recruiting
NCT07498465 2026-05-05
A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia
Children's Oncology Group
Phase 1 Withdrawn
NCT03007147 2026-05-04
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Children's Oncology Group
Phase 3 Active not recruiting
NCT06289673 2026-05-01
Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
St. Jude Children's Research Hospital
Phase 4 Recruiting
NCT06390319 2026-05-01
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
St. Jude Children's Research Hospital
Phase 2 Recruiting
NCT06533748 2026-05-01
Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma
St. Jude Children's Research Hospital
Phase 2 Recruiting
NCT05761171 2026-04-21
A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia
Children's Oncology Group
Phase 2 Active not recruiting
NCT05292664 2026-03-12
Venetoclax Basket Trial for High Risk Hematologic Malignancies
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT00400946 2026-02-13
05-001: Treatment of Acute Lymphoblastic Leukemia in Children
Dana-Farber Cancer Institute
Phase 3 Completed
NCT03913559 2026-02-12
Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia
St. Jude Children's Research Hospital
Phase 2 Terminated
NCT03020030 2026-01-22
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents
Dana-Farber Cancer Institute
Phase 3 Active not recruiting
NCT07072585 2025-12-31
Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)
Children's Oncology Group
Phase 2/3 Not yet recruiting
NCT00136435 2025-10-20
A Study in Adults With Untreated Acute Lymphoblastic Leukemia
Dana-Farber Cancer Institute
Phase 2 Completed
NCT05974410 2025-10-02
Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients
AVM Biotechnology Inc
Available
NCT04546399 2025-09-10
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT03817320 2025-06-17
PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1/2 Active not recruiting
NCT00476190 2025-06-12
ALL Adult Consortium Trial: Adult ALL Trial
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02303821 2025-06-04
Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia
Amgen
Phase 1 Completed
NCT03792256 2025-03-21
Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)
Children's Oncology Group
Phase 1 Completed
NCT02828358 2025-02-27
Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement
National Cancer Institute (NCI)
Phase 2 Completed
NCT05476770 2024-12-06
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1 Recruiting
NCT00557193 2024-07-15
Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Children's Oncology Group
Phase 3 Completed
NCT01186328 2024-02-01
EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1 Terminated
NCT05320380 2023-09-01
A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat
Children's Oncology Group
Phase 1/2 Withdrawn
NCT01614197 2023-07-27
A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1 Completed
NCT03349281 2022-10-20
Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL
University of Miami
Phase 1 Completed
NCT01700946 2022-09-28
Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma
St. Jude Children's Research Hospital
Phase 2 Completed
NCT01451515 2022-06-28
NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma
St. Jude Children's Research Hospital
Phase 2 Completed
NCT00006455 2022-05-31
ALCL 99
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Completed
NCT02043587 2022-05-02
Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma
University of California, San Diego
Phase 2 Terminated
NCT02481310 2022-02-21
Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma
Northwestern University
Phase 1/2 Unknown
NCT05049473 2021-09-20
Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.
PETHEMA Foundation
Phase 2 Unknown
NCT00720109 2020-04-13
Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 2/3 Completed
NCT00853008 2020-04-07
LAL-AR/2003
PETHEMA Foundation
Phase 4 Completed
NCT01540812 2020-03-09
Treatment of Acute Lymphoblastic Leukemia HIGH RISK BCR / ABL NEGATIVE IN ADULTS
PETHEMA Foundation
Completed
NCT00185692 2019-12-04
Allogeneic Transplantation From Related Haploidentical Donors
Stanford University
Phase 2 Completed
NCT02535806 2019-08-13
Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults
Children's Mercy Hospital Kansas City
Phase 2 Terminated
NCT00133991 2018-09-17
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00002865 2018-08-10
High-Intensity, Brief-Duration Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia
Wake Forest University Health Sciences
Phase 2 Completed
NCT00392834 2018-06-06
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma
AIDS Malignancy Consortium
Phase 2 Completed
NCT00482053 2018-05-14
Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT
Stanford University
Phase 2 Terminated
NCT00354107 2018-03-14
Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT02419755 2018-03-07
Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies
St. Jude Children's Research Hospital
Phase 2 Terminated
NCT00098839 2017-12-12
Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)
Children's Oncology Group
Phase 1/2 Completed
NCT00186628 2017-11-28
Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD
Stanford University
Phase 2 Completed